Apellis Pharmaceuticals, Inc. (APLS)
41.12
+0.15
(+0.37%)
USD |
NASDAQ |
May 06, 16:00
41.06
-0.06
(-0.15%)
After-Hours: 20:00
Apellis Pharmaceuticals SG&A Expense (TTM) : 550.26M for Dec. 31, 2025
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Biogen, Inc. | 2.468B |
| Eli Lilly & Co. | 11.56B |
| Agios Pharmaceuticals, Inc. | 187.06M |
| Scholar Rock Holding Corp. | 176.20M |
| Kezar Life Sciences, Inc. | 18.51M |